Author Archives: Bruno Quinney

#AL Amyloidosis #Clinical trial #Financing

Protego raises $130 million to advance AL amyloidosis treatment 

Biotechnology company Protego Biopharma has raised $130 million to advance its first-in-class AL amyloidosis programme to clinical trial.  The proceeds from the over-subscribed Series B financing round will advance Protego’s lead candidate, PROT-001, into a pivotal clinical trial for AL amyloidosis. PROT-001 works by stabilising immunoglobulin light chains and preventing amyloid buildup, addressing disease at its root cause… Read More

#Business & Investment #News

ALS concept
#ALS #Axoltis Pharma #Financing

Axoltis Pharma raises €18 million to advance ALS drug 

Biotech company Axoltis Pharma has raised €18 million to accelerate the development of an amyotrophic lateral sclerosis (ALS) drug candidate.  The closure of a Series A financing round will enable Axoltis to develop lead candidate NX210x, currently in Phase II clinical trials in patients with ALS.  The financing round was co-led by FIDAT Ventures and Cenitz with… Read More

#Business & Investment #News

#Advanced Therapies #Cancer research #Cell therapy #Pancreatic cancer

Tumour-regressing cell therapy advanced towards clinic 

Drug discovery company Lunai Bioworks has secured its first Letter of Intent (LOI) to license its next-generation immune cell therapy, advancing the treatment to clinic.  Lunai’s Dendritic Cell Combination Therapy (DCCT) achieved complete regression of both primary and metastatic pancreatic tumours with no recurrence in humanised pre-clinical models. Read More

#Cancer Research #News

#ALS #Antibody drug conjugate (ADC) #Breast cancer #DDW Highlights podcast #DDW Turning Science into Business Symposium #Gene therapy #Hunter Syndrome #Oncology

DDW Highlights: 2 December 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, gene therapies provided solutions for complex conditions, most notably in Hunter syndrome… Read More

#Podcasts

Subcutaneous injection
#ABPI #Clinical trial #UK #UK government

Decline in trial recruitment denying patients, ABPI warns 

The decline in commercial clinical trial recruitment is denying patients participation in cutting-edge research, the Association of the British Pharmaceutical Industry (ABPI) has warned.  According to the ABPI’s annual clinical trials report, the number of patients recruited into UK industry clinical trials fell by 25% between 2022/23… Read More

#News

#ALS #Antibody drug conjugate (ADC) #Breast cancer #Cancer research #DDW Turning Science into Business Symposium #Gene therapy #Hunter Syndrome #Neurodegenerative disorders #Oncology #The University of Manchester #University of California San Diego

This week in Drug Discovery (24 – 28 November) 

News round-up for 24 – 28 November by Bruno Quinney, Content Team at DDW.  This week in drug discovery, gene therapies are providing solutions for complex conditions, most notably in Hunter syndrome but also in amyotrophic lateral sclerosis. Elsewhere, an antibody-drug conjugate precision therapy could prevent breast cancer. … Read More

#News

#AI #Citius Pharmaceuticals #Immunotherapy

Citius Oncology prepares to launch immunotherapy treatment 

Citius Oncology has partnered with technology company Verix to advance the commercial launch of its novel immunotherapy Lymphir.  Lymphir is used for the treatment of adult patients with elapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. The treatment was previously approved by the US… Read More

#News

Diffuse large B-cell lymphoma
#Acute Myeloid Leukaemia #Biotech #CAR-T #Lymphoma

Imviva to present data on CAR-T pipeline 

Biotechnology company Imviva Biotech is set to present data on its CAR-T pipeline at the American Society of Haematology (ASH) Annual Meeting.  Imviva will reveal progress in allogeneic cell therapy candidates being developed for multiple haematological conditions, including T-cell acute lymphoblastic leukaemia, lymphoblastic lymphoma, acute myeloid leukaemia, B-cell… Read More

#Cancer Research #News

Cancer research in laboratory
#Breast cancer #Cancer research #Financing

Zetagen raises $12 million to advance breast cancer treatment 

Biopharmaceutical company Zetagen Therapeutics has raised over $12 million to proceed with first-of-its-kind, intratumoural treatments for metastatic and primary breast cancer.  The company announced the closing of its Series B1 financing round, raising $12.9 million. Proceeds will support the advancement of Zetagen’s lead candidate, ZetaMet (Zeta-BC-003), towards commercialisation, the clinical development of ZetaMast (Zeta-MBC-005), and the completion of preclinical studies and GMP manufacturing of ZetaPrime (Zeta-PBC-007).  The… Read More

#Business & Investment #News

Multiple myeloma
#Myeloma #National Institute for Health and Care Excellence (NICE) #NHS

NICE recommends myeloma treatment for NHS patients

The National Institute for Health and Care Excellence (NICE) has recommended Talvey (talquetamab) for use in the NHS for treating relapsed or refractory myeloma (RRMM) in adults.  Talquetamab, developed by Johnson & Johnson, is a first-in-class bispecific antibody targeting the GPRC5D receptor on myeloma cells. The treatment redirects T-cells to… Read More

#News #Regulatory

#DDW Turning Science into Business Symposium

DDW Symposium: Bringing science and business insight under one roof

Described by one delegate as “insightful with a good balance of deep scientific knowledge and impact”, the DDW Turning Science into Business Symposium, offered a focused afternoon on drug discovery science, technology, opportunity and success for the future. This inaugural event attracted senior figures from pharma, biotech, investment and technology… Read More

#News

#Education #STEM #UK

Horiba initiative to widen UK scientific participation 

Global manufacturer Horiba UK has announced the launch of the Horiba Foundation UK, a new initiative to advance scientific research and broaden STEM participation. The Horiba Foundation UK will work with universities and their established mechanisms through a range of initiatives, including grants, scholarships,… Read More

#News

#Business #GLP-1 #Obesity #PrecisionLife

Test could trigger reimbursement for obesity drugs 

Patients could soon be reimbursed for ineffective anti-obesity drugs after human omics company Ovation and precision medicine company PrecisionLife partnered to develop a first-of-its-kind test.  The collaboration between the companies aims to develop drug-response biomarkers for glucagon-like peptide-1 receptor agonist (GLP-1) therapies. The resulting findings could form the basis… Read More

#News

Parkinson's disease
#Japan #Neurodegenerative disorders #Parkinson's

Research reveals therapeutic target for Parkinson’s 

Researchers in Japan have revealed a potential new therapeutic target for Parkinson’s disease.  Scientists at Juntendo University found that liquid droplets of the protein ubiquilin-2 act as a catalyst for the aggregation of a-synuclein, a protein in the brain which is associated with neurodegenerative disorders. Ubiquilin-2 droplets… Read More

#News

Cancer cells
#Antibody drug conjugate (ADC) #Breast cancer #University of California San Diego

ADC precision therapy could prevent breast cancer, study shows 

New research has identified a precision therapy which could stop breast cancer at the source.  Researchers at the University of California San Diego School of Medicine used an antibody-drug conjugate (ADC) to target a cell-surface protein known as FZD7. FZD7 is present on cells with high tumour-initiating potential in… Read More

#Cancer Research #News